Regulators are making even more stringent demands for larger and longer clinical trials that give better proof of efficacy and are more likely to pick up safety signals.
With ongoing cost pressures across the business, companies are always on the lookout for strategies and methods that might accelerate a product’s journey from idea to marketing authorisation, reducing R&D costs and maximising the length of time a product has to recoup its development costs before its patent expires and it’s exposed to generic or biosimilar competition.
To request more information or to find out more, download the white paper.
